This is the golden age of investing in artificial intelligence!
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive.
Invest in this red-hot industry at pre-IPO prices.
Justin J. McAnear, insider at 10x Genomics

Justin J. McAnear Insider Information

CFO of 10x Genomics
Justin McAnear has served as Chief Financial Officer of 10x Genomics since 2018, bringing over 20 years of financial and operational leadership experience in dynamic, high-growth environments. Prior to joining 10x, Justin was the Vice President of Worldwide Finance and Operations at Tesla, where he helped scale the company through the Model X and Model 3 launches. Justin also served as a Finance Director at Apple in Corporate FP&A and Worldwide Operations. Justin began his career at Johnson & Johnson where he held various roles. Justin served over nine years in the U.S. Navy as an aviator, and is a graduate of the U.S. Naval Academy in Annapolis, MD, where he earned his B.S. degree in Systems Engineering. He also holds a M.B.A. in Finance from the University of San Diego.

What is Justin J. McAnear's net worth?

The estimated net worth of Justin J. McAnear is at least $2.99 million as of May 13th, 2022. Mr. McAnear owns 60,046 shares of 10x Genomics stock worth more than $2,994,494 as of May 20th. This net worth approximation does not reflect any other investments that Mr. McAnear may own. Additionally, Mr. McAnear receives an annual salary of $330,000.00 as CFO at 10x Genomics. Learn More about Justin J. McAnear's net worth.

How old is Justin J. McAnear?

Mr. McAnear is currently 46 years old. There are 5 older executives and no younger executives at 10x Genomics. The oldest executive at 10x Genomics is Mr. Bradford J. Crutchfield, Chief Commercial Officer, who is 59 years old. Learn More on Justin J. McAnear's age.

What is Justin J. McAnear's salary?

As the CFO of 10x Genomics, Inc., Mr. McAnear earns $330,000.00 per year. There are 4 executives that earn more than Mr. McAnear. The highest earning executive at 10x Genomics is Dr. Serge Saxonov Ph.D., Co-Founder, CEO & Director, who commands a salary of $654,990.00 per year. Learn More on Justin J. McAnear's salary.

How do I contact Justin J. McAnear?

The corporate mailing address for Mr. McAnear and other 10x Genomics executives is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. 10x Genomics can also be reached via phone at 925-401-7300 and via email at [email protected] Learn More on Justin J. McAnear's contact information.

Has Justin J. McAnear been buying or selling shares of 10x Genomics?

Justin J. McAnear has not been actively trading shares of 10x Genomics in the last ninety days. Learn More on Justin J. McAnear's trading history.

Who are 10x Genomics' active insiders?

10x Genomics' insider roster includes Bradford Crutchfield (Insider), Benjamin Hindson (Insider), Sridhar Kosaraju (Director), Justin McAnear (CFO), Serge Saxonov (CEO), and John Stuelpnagel (Director). Learn More on 10x Genomics' active insiders.

Are insiders buying or selling shares of 10x Genomics?

During the last year, 10x Genomics insiders bought shares 1 times. They purchased a total of 158 shares worth more than $6,397.42. During the last year, insiders at the sold shares 54 times. They sold a total of 572,185 shares worth more than $89,552,571.75. The most recent insider tranaction occured on May, 13th when CFO Justin J Mcanear bought 158 shares worth more than $6,397.42. Insiders at 10x Genomics own 11.6 % of the company. Learn More about insider trades at 10x Genomics.

Information on this page was last updated on 5/13/2022.

Justin J. McAnear Insider Trading History at 10x Genomics

See Full Table

Justin J. McAnear Buying and Selling Activity at 10x Genomics

This chart shows Justin J. Mcanear's buying and selling at 10x Genomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

10x Genomics Company Overview

10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $49.87
Low: $47.00
High: $51.10

50 Day Range

MA: $60.90
Low: $39.65
High: $82.41

2 Week Range

Now: $49.87
Low: $36.76
High: $208.99

Volume

1,914,583 shs

Average Volume

2,046,084 shs

Market Capitalization

$5.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.